Trial Examining Methods for Antidepressant Discontinuation (TEMPO)
Key facts
- Where
- Amsterdam és Nijmegen, HollandiaSee the 2 sites
- Phase
- 4. fázis
Where in Hollandia
- Amsterdam UMC StichtingAmsterdam, HollandiaNo longer taking part
- Radboud Universitair Medisch Centrum (Radboudumc)Nijmegen, HollandiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC Stichting
- Trial code
- EU 2024-511997-66-00
- Record updated
- 2025. április 24.
- Original description
TEMPO is a double-blind placebo-controlled RCT which aims to investigate how antidepressants should best be discontinued. To this end, TEMPO will compare two tapering strategies in patients with stable remitted MDD who use either PAR or VLX.Read full original descriptionShow less
TEMPO is a double-blind placebo-controlled RCT which aims to investigate how antidepressants should best be discontinued. To this end, TEMPO will compare two tapering strategies in patients with stable remitted MDD who use either PAR or VLX.
Inclusion: Age 18-75 years; Stable ≥6-month (≥1 year in recurrent MDD) remission of MDD, confirmed with a score of 12 or lower on the Patient Health Questionnaire 9 (PHQ-9); Use of paroxetine (20-50mg) or venlafaxine (75-375mg); Previous MDD episode and current remission confirmed with semi-structured psychiatric interview (MINI); Willing and able to provide informed consent and follow the procedures necessary to participate in the study.
Exclusion: Severe drug/alcohol addiction that warrants clinical attention; Psychotic or bipolar disorder; Use of other antidepressants (starting at the minimally effective dose), augmentation treatment (e.g. aripiprazole, olanzapine, lithium) and/or chronic high doses of benzodiazepines (daily use of >10mg diazepam equivalent); Insufficient mastery of Dutch language.